Abacus Health Products, Inc. (CSE: ABCS) today announced further growth in the distribution and availability of their line of CBDMEDIC™ products.
Abacus Health Products, Inc. (CSE: ABCS) announced the closing of its bought deal offering of 2,464,450 units including the exercise, in full, of the Underwriters’ over-allotment option for gross proceeds of $34,502,300.
Abacus Health Products, Inc. (CSE: ABCS) released the financial results of its operating subsidiary, Abacus Health Products, Inc., a Delaware corporation, for the 12-month period ending December 31, 2018, being a period completed prior to the closing of the Company’s reverse takeover transaction with Abacus U.S. completed on January 29, 2019 .
James Barkat has been named Vice President of Marketing for Abacus. Prior to joining the Company, Mr. Barkat spent over ten years at Sanofi Consumer Health, where he most recently served as U.S.
These new orders from five U.S. retail chains, including CVS Pharmacy, Weis Markets, and Pharmacare
Inc, bring CBDMEDIC products to over 1100 pharmacy and supermarket retail locations throughout the
TORONTO, Feb. 6th, 2019 Abacus Health Products, Inc (CSE: ABCS) (“Abacus”) announced today that it is launching an advanced skincare line, within its CBDMEDIC family of products, for the treatment of Acne, Eczema, and Itch & Rash. All products utilize FDA monograph Active Pharmaceutical Ingredients, cannabinoids, and are blended with natural and organic ingredients. This […]